Corbevax gets DCGI Nod as Heterologous Booster Dose

Story Highlights
  • Corbevax approved as heterologous booster dose.
  • The booster dose can be administered for individuals above 18.
  • Corbevax was approved for EUA by DCGI in February.

New Delhi: India’s drugs regulator on Saturday approved Hyderabad-based Biological E’s anti-Covid vaccine as a heterologous booster dose for adults having already taken two doses of Covishield or Covaxin vaccine, according to a company statement, making it the first vaccine to have been approved as a booster.

“CORBEVAX® COVID-19 vaccine has been approved by the Drug Controller General of India (DCGI) as a heterologous COVID-19 booster dose to individuals aged 18 years and above after 6 months of administration of primary vaccination (two doses) of COVAXIN or COVISHIELD vaccines for restricted use in emergency situation. BE’s CORBEVAX® is the first such vaccine in India to be approved as a heterologous COVID-19 booster,” said the company in a statement.

Corbevax- is India’s first indigenously developed protein sub-unit vaccine against COVID-19. Corbevax uses a recombinant protein platform to target the spike protein on the virus particle’s surface.

Three months, Corbevax received emergency use authorisation (EUA) from the DCGI for use on kids aged 12 years and above.

Related Articles

Back to top button